Mammoth Biosciences's CRISPR-based COVID-19 test receives NIH fundings through RADx program

CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Accleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address the testing shortages across the U.S. Mammoth's CRISPR-based approach could potentially offer a significant solution to current testing bottlenecks, because it's a very different kind of test when compared to existing methods based on PCR technology.

https://ift.tt/3gktHI3 from Yahoo Tech https://ift.tt/3hNPtEm
via IFTTT